ZyVersa Therapeutics (ZVSA) shifts trading from OTCQB to OTC Pink
Rhea-AI Filing Summary
ZyVersa Therapeutics, Inc. reports a change in the trading venue for its common stock. Effective July 16, 2026, the company’s common stock, par value $0.0001 per share and trading under the symbol ZVSA, ceased trading on the OTCQB® Venture Market and commenced trading on the OTC Pink Limited Market.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Par value per share: $0.0001 per share
Effective date of market change: July 16, 2026
Commission File Number: 001-41184
3 metrics
Par value per share
$0.0001 per share
Par value of ZyVersa Therapeutics, Inc. common stock
Effective date of market change
July 16, 2026
Date trading moved from OTCQB Venture Market to OTC Pink Limited Market
Commission File Number
001-41184
SEC Commission File Number for ZyVersa Therapeutics, Inc.
Key Terms
OTCQB® Venture Market, OTC Pink Limited Market, emerging growth company
3 terms
OTCQB® Venture Market market
"ceased trading on the OTCQB® Venture Market and commenced trading on"
OTC Pink Limited Market market
"commenced trading on the OTC Pink Limited Market"
OTC Pink Limited Market is an over‑the‑counter trading tier for stocks that are not listed on major exchanges and provide only limited public information about their operations and financials. It matters to investors because lower disclosure increases uncertainty and risk—prices can be volatile and it can be harder to verify value or spot problems, like buying an unlabeled used item at a flea market where you don’t know its history or condition.
emerging growth company regulatory
"meets the definition of an emerging growth company under Rule 12b-2"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What market change did ZyVersa Therapeutics (ZVSA) disclose?
ZyVersa Therapeutics disclosed that its common stock stopped trading on the OTCQB® Venture Market and began trading on the OTC Pink Limited Market, effective July 16, 2026.
When did ZyVersa Therapeutics (ZVSA) begin trading on the OTC Pink Limited Market?
ZyVersa’s common stock began trading on the OTC Pink Limited Market on July 16, 2026. On that date, trading on the OTCQB® Venture Market ceased and shifted to the new over-the-counter tier.
Did ZyVersa Therapeutics (ZVSA) change its state of incorporation or headquarters?
No changes were reported to ZyVersa’s Delaware incorporation or its principal executive offices at 2436 N Federal Hwy, Suite 466, Lighthouse Point, Florida 33064. The disclosure focused on the trading market for its common stock.
Is ZyVersa Therapeutics (ZVSA) identified as an emerging growth company?
Yes. ZyVersa is identified as an emerging growth company under applicable Exchange Act rules. This status appears alongside the disclosure about its common stock’s quotation on the OTC Pink Limited Market.